AbbVie has acquired Aliada Therapeutics for $1.4 billion to improve drug delivery for Alzheimer’s disease treatments. Aliada’s technology allows antibodies to cross the blood-brain barrier more easily, potentially leading to more effective therapies. The lead program, ALIA-1758, uses a platform technology called Modular Delivery to enhance brain delivery. AbbVie has been investing in Alzheimer’s drug research, including partnerships with Alector and the recent acquisition of Syndesi Therapeutics. The acquisition of Aliada strengthens AbbVie’s research and development capabilities in neuroscience and will help accelerate the development of next-generation therapies for neurological disorders and other diseases.
Source link
AbbVie Adds Another Alzheimer’s Prospect With $1.4B Aliada Therapeutics Acquisition
